Extended hepatitis C treatment after liver transplant may benefit patients

May 02, 2010

Extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate, according to a study by Henry Ford Hospital.

"We found that patients who achieved a sustained virological response were more likely to have had extended treatment after transplant," says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study.

"In the study, we saw a trend toward decreased mortality as sustained virological response was found to be associated with a 100 percent five-year survival rate vs. 86 percent for those without."

Although, statistically insignificant, the trend could show significance with longer follow-up and a larger sample size, explains Dr. Moeller.

Study results will be presented May 2 at the Digestive Diseases Week conference in New Orleans.

The study looked at 241 consecutive patients from 1999-2006. Patients were offered treatment if they tested positive for , had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable for a minimum of three months. Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.

Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed. This is in contrast to typical relapse rates of 30-35 percent in non-transplant patients treated with standard therapy. Genotype 1 patients failed more than genotype 2 or 3 patients in achieving sustained virological response (27 percent vs. 70 percent).

Dr. Moeller notes that 35 percent of patients who went on to achieve sustained virological response first became virus-negative at or following week 24.

"Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance with extended treatment," says Dr. Moeller.

Explore further: Soy supplements don't improve asthma

Related Stories

Researcher Announced Cure for Hepatitis C

May 22, 2007

The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher ...

Shorter HCV treatment shows notable success

Jan 02, 2008

[B]It also lowers costs and the risk of serious side effects[/B] Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates sim ...

Recommended for you

Factors linked to development of celiac disease identified

13 hours ago

(HealthDay)—Certain perinatal factors, including sex of the child, maternal celiac disease, and type 1 diabetes, are associated with development of celiac disease in children, according to a study published ...

WHO shake-up approved after Ebola debacle

18 hours ago

The World Health Organization got the go-ahead Tuesday for a sweeping shake-up, including a $100-million war chest to battle future emergencies following the Ebola fiasco.

Soy supplements don't improve asthma

19 hours ago

Despite previous findings suggesting a link between soy intake and decreased asthma severity, a new study from Northwestern Medicine and the American Lung Association Asthma Clinical Research Network shows ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.